Federal Register / Vol. 71, No. 172 / Wednesday, September 6, 2006 / Notices 52549 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 

Comment Request; Preventing Motor 

Vehicle Crashes Among Young Drivers 

Summary: Under the provisions of 

Section 3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Institute of Child Health and Human 

Development (NICHD), the National 

Institutes of Health (NIH) has submitted 

to the Office of Management and Budget 

(OMB) a request for review and 

approval of the information collection 

listed below. This proposed information 

collection was previously published in 

the Federal Register on June 13, 2006, 

page 34142, and allowed 60-days for 

public comment. No public comments 

were received. The purpose of this 

notice is to allow an additional 30 days 

for public comment. The National 

Institutes of Health may not conduct or 

sponsor, and the respondent is not 

required to respond to, an information 

collection that has been extended, 

revised, or implemented on or after 

October 1, 1995, unless it displays a 

currently valid OMB control number. 

Proposed Collection 

Title: Preventing Motor Vehicle 

Crashes Among Young Drivers, OMB 

No. 0925–new. 

Type of Information Collection 

Request: New. 

Need and Use of Information 

Collection: Motor vehicle crash risk is 

particularly elevated among novice 

young drivers during the first six 

months and 1000 miles of independent 

driving. Previously, researchers in the 

Prevention Research Branch of the 

NICHD have demonstrated the efficacy 

of the Checkpoints Program for 

increasing parental management of teen 

driving and reducing exposure to high 

risk driving conditions during the first 

12 months after licensure. The current 

research seeks to test the effectiveness of 

providing an educational program 

entitled The Checkpoints Program to 

facilitate parental management of teen 

driving when delivered at motor vehicle 

administration offices at the time the 

teen obtains a permit, at the time of 

license, or at both permit and license. 

Frequency of Response: 3 times over 

two years. 

Affected Public: Individuals or 

households. 

Type of Respondents: Adolescents 

and parents/guardians. 

The annual reporting burden is as 

follows: Estimated Number of 

Respondents: 4000; Estimated Number 

of Responses per Respondent: 3; 

Average Burden Hours Per Response: 

35; and Estimated Total Annual Burden 

Hours Requested: 4,200. The annualized 

cost to respondents is estimated at: 

$42,000 (based on $10 per hour). 

There are no Capital Costs to report. 

There are no Operating or Maintenance 

Costs to report. 

Type of respondents 

Estimated 

number of 

respondents 

Estimated 

number of 

responses per 

respondent 

Average burden hours per 

response 

Estimated total 

annual burden 

hours 

requested 

Parents/guardians ............................................................................................ 2000 3 .35 2100 

Teens ............................................................................................................... 2000 3 .35 2100 

Total .......................................................................................................... 4000 3 .35 4200 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the function of the 

agency, including whether the 

information will have practical utility; 

(2) The accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) Ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

Ways to minimize the burden of the 

collection of information on those who 

are to respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, should be directed to the: Office 

of Management and Budget, Office of 

Regulatory Affairs, New Executive 

Office Building, Room 10235, 

Washington, DC 20503, Attention: Desk 

Officer for NIH. To request more 

information on the proposed project or 

to obtain a copy of the data collection 

plans and instruments, contact Dr. 

Bruce Simons-Morton, Chief, Prevention 

Research Branch, DESPR, NICHD, NIH, 

6100 Executive Blvd., Rm 7B05, MSC 

7510, Bethesda, MD 20892–7510; (301) 

496–5674; e-mail: 

mortonb@mail.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30-days of the date of 

this publication. 

Dated: August 25, 2006. 

Paul Johnson, 

Project Clearance Liaison, NICHD, National 

Institutes of Health. 

[FR Doc. E6–14680 Filed 9–5–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 


rwilkins on PROD1PC63 with NOTICES
52550 Federal Register / Vol. 71, No. 172 / Wednesday, September 6, 2006 / Notices 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Ghost Native-PAGE With Colorless 

Compound Derived From Coomassie 

Brilliant Blue 

Description of Technology: Protein 

staining dyes such as serva blue G or 

Coomassie blue are used to enhance the 

separation of protein complexes by 

binding to the proteins and 

differentially enhancing the net charge 

of the complexes improving the 

separation of the complexes using 

electrophoresis procedures. However, 

the intense blue color of Coomassie 

stains interferes with immunobloting 

and in gel colormetric or fluorescent 

studies. Available for licensing and 

commercial development is a colorless 

molecule that will bind and enhance the 

differential surface charge on protein 

complexes. The molecule has been 

demonstrated to work as well as 

Coomassie blue but will not interfere in 

gel assays critical for most 

investigations. This approach provides 

biochemists interested in protein 

complexes in biological tissues with the 

ability to separate protein complexes 

and perform in gel assays saving time 

and resources in this important 

emerging field. 

The compound and methods of its use 

is for polyacrylamide gel electrophoresis 

(PAGE) and related gel techniques for 

the analysis of protein complexes and 

defects in the same. Such analysis can 

be extended to the detection of various 

diseases, e.g., Alzheimer’s disease or 

Parkinson’s disease. One such 

compound has the following formula: 

Applications: Alzheimer’s disease 

diagnostics; Parkinson’s disease 

diagnostics. 

Market: Protein-protein interaction 

biochemistry. 

Development Status: Early-stage. 

Inventors: Robert Balaban (NHLBI), 

Gary Griffiths (NHLBI), Ksenia Blinova 

(NHLBI), et al. 

Publications: 

1. MM Camacho-Carvajal, et al. Twodimensional Blue native/SDS gel 

electrophoresis of multi-protein 

complexes from whole cellular lysates: 

a proteomics approach. Mol Cell 

Proteomics. 2004 Feb; 3(2):176–182. 

2. R Van Coster, et al. Blue native 

polyacrylamide gel electrophoresis: a 

powerful tool in diagnosis of oxidative 

phosphorylation defects. Pediatr Res. 

2001 Nov; 50(5):658–665. 

3. I Whittig and H Schagger. 

Advantages and limitations of clearnative PAGE. Proteomics. 2005 Nov; 

5(17):4338–4346. 

Patent Status: U.S. Provisional 

Application No. 60/835,069 filed 03 

Aug 2006 (HHS Reference No. E–218–

2006/0-US–01). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Michael A. 

Shmilovich, Esq.; 301/435–5019; 

shmilovm@mail.nih.gov. 

In Vivo Non-Invasive Diagnostic 

Method Using Magnetic Resonance 

Spectroscopy of Aspartate 

Transaminase 

Description of Technology: This 

invention describes a method for noninvasively diagnosing various diseases 

using magnetic resonance spectroscopy 

of aspartate transaminase (AST). The 

diagnostic market is a multi-billion 

dollar market, with a need for more 

efficient non-invasive techniques, 

markers and methods of diagnosis. 

In particular, this is a novel noninvasive method for using carbon-13 

magnetization transfer effects to 

determine and evaluate in vivo aspartate 

transaminase (AST) activity and levels 

in an organ, including the brain, as a 

biomarker of disease and certain 

neurological disorders. This comprises 

performing in vivo magnetization 

transfer spectroscopy, and determining 

the change in magnetic resonance signal 

intensity of reactants in AST catalyzed 

reaction. 

AST activity is known to change as a 

result of tissue damage and necrosis in 

a variety of diseases. AST activity is 

routinely assessed in serum of patients 

as a non-invasive means of identifying 

and following up on disease 

progression. Furthermore, brain levels 

of AST are altered in certain diseases 

such as Huntington’s Disease, 

olivopontocerebellar atrophy and 

epilepsy, but the blood-brain barrier 

prevents AST from entering serum and 

being readily measured. Brain AST 

levels in living patients can be 

measured by brain biopsies, which are 

expensive and dangerous. This 

invention overcomes this problem by 

measuring AST activity in the brain by 

using magnetization transfer effect. This 


rwilkins on PROD1PC63 with NOTICESEN06SE06.002</GPH>
Federal Register / Vol. 71, No. 172 / Wednesday, September 6, 2006 / Notices 52551 

can help diagnose or follow up on the 

progress of a variety of diseases, 

including Huntington’s Disease, 

olivopontocerebellar atrophy, epilepsy, 

schizophrenia, as well as hepatitis, 

cirrhosis, cholangitis, Gilbert’s diseases, 

muscular dystrophy, leukemia, kidney 

inflammation, cardiac infarction, or the 

presence of a tumor. Thus, tissue AST 

activity may become a novel marker of 

brain disorders which has been 

inaccessible using current clinical 

technologies. 

Applications and Market: Diagnosis 

and monitoring disease status in a 

variety of diseases, including 

Huntington’s Disease, 

olivopontocerebellar atrophy, epilepsy, 

schizophrenia, as well as hepatitis, 

cirrhosis, cholangitis, Gilbert’s diseases, 

muscular dystrophy, leukemia, kidney 

inflammation, cardiac infarction, or the 

presence of a tumor. The diagnostic 

market is a multi-billion dollar market, 

with a need for more efficient noninvasive techniques, markers and new 

methods of diagnosis. 

Patent Status: U.S. Patent Application 

No. 11/356,214 filed 21 Feb 2006 (HHS 

Reference No. E–231–2005/0–US–02). 

Inventors: Dr. Jun Shen (NIMH). 

Publication: J Shen. In vivo carbon-13 

magnetization transfer effect: detection 

of aspartate aminotransferase reaction. 

Magn Reson Med. 2005 Dec; 54(6):1321–

1326. 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Chekesha 

Clingman, Ph.D.; 301/435–5018; 

clingman@mail.nih.gov. 

Dated: August 29, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–7439 Filed 9–5–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Alternative Medicine; Amended Notice 

of Meeting 

Notice is hereby given of a change in 

the meeting of the National Advisory 

Council for Complementary and 

Alternative Medicine, September 8, 

2006, 9 a.m. to September 8, 2006, 4 

p.m., National Institutes of Health, 

Neuroscience Building, 6001 Executive 

Boulevard, Rooms C & D, Rockville, MD 

20852, which was published in the 

Federal Register on July 28, 2006, 71 FR 

42860. 

This meeting is being amended due to 

the start time change for the Open 

session from 2 p.m. to 1:30 p.m. The 

meeting is partially Closed to the public. 

Dated: August 28, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–7436 Filed 9–5–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

NIMH Eating Disorders Grant Application 

Review. 

Date: September 29, 2006. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, (Telephone 

Conference Call). 

Contact Person: Bettina D. Osborn, Ph.D., 

Scientific Review Administrator, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

6001 Executive Blvd., Room 6154, MSC 9609, 

Rockville, MD 20852–9609, 301–443–1178, 

acunab@mail.nih.gov. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

Mental Health Centers for Intervention 

Development and Applied Research (CIDAR). 

Date: October 12–13, 2006. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Park Hotel, 8400 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: A. Roger Little, Ph.D., 

Scientific Review Administrator, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

6001 Executive Blvd., Room 6157, MSC 9609, 

Rockville, MD 20852–9609, 301–402–5844, 

alittle@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.242, Mental Health Research 

Grants; 93.281, Scientist Development 

Award, Scientist Development Award for 

Clinicians, and Research Scientist Award; 

93.282, Mental Health National Research 

Service Awards for Research Training, 

National Institutes of Health, HHS) 

Dated: August 28, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–7434 Filed 9–5–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institutes of Diabetes and 

Digestive and Kidney Diseases; 

Amended Notice of Meeting 

Notice is hereby given of changes in 

the meeting of the National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council, September 20, 2006, 8:30 a.m. 

to September 21, 2006, 12 p.m., 

National Institutes of Health, Building 

31, 31 Center Drive, Bethesda, MD 

20892, which was published in the 

Federal Register on August 18, 2006, 71 

FR 47820–47821. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council. 

Date: September 20–21, 2006. 

Open: September 20, 2006, 8:30 a.m. to 12 

p.m. 

Agenda: To present the Director’s Report 

and other scientific presentations. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892. 

Open: September 20, 2006, 4 p.m. to 5 p.m. 

Agenda: Report from the NIH Director. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892. 

Closed: September 21, 2006, 9:45 a.m. to 

10:15 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892. 

Open: September 21, 2006, 10:15 a.m. to 12 

p.m. 

Agenda: Continuation of the Director’s 

Report and other scientific presentations. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892. 

Contact Person: Brent B. Stanfield, Ph.D., 

Director, Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy Blvd., 


rwilkins on PROD1PC63 with NOTICES